Announcements Trials
Browse Landscape

Phase

Phase 3 1Phase 1 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Conditions

Breast Neoplasms 592Neoplasms 296Carcinoma, Non-Small-Cell Lung 284Prostatic Neoplasms 266Colorectal Neoplasms 213Multiple Myeloma 181Lung Neoplasms 149Neoplasm Metastasis 139Leukemia, Myeloid, Acute 125Leukemia 120Lymphoma 114Lymphoma, Follicular 113Stomach Neoplasms 105Lymphoma, Non-Hodgkin 102Colonic Neoplasms 98Ovarian Neoplasms 96Rectal Neoplasms 95Precursor Cell Lymphoblastic Leukemia-Lymphoma 94Uterine Cervical Neoplasms 93Head and Neck Neoplasms 92Leukemia, Lymphocytic, Chronic, B-Cell 91Pain 90Carcinoma, Hepatocellular 86Pancreatic Neoplasms 81Melanoma 78Lymphoma, Large B-Cell, Diffuse 77Papillomavirus Infections 68Recurrence 66Squamous Cell Carcinoma of Head and Neck 64Parkinson Disease 4, Autosomal Dominant Lewy Body 62

Interventions

Bupivacaine 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 3 × Completed × Peritoneal Cancer × Clear all
NCT03359811 2022-02-18

Four Quadrants Transverse Abdominus Plane (4Q-TAP) Block With Plain and Liposomal Bupivacaine vs. Thoracic Epidermal Analgesia (TEA) in Patients Undergoing Cytoreductive Surgery With Hyperthermic Intraperitoneal Chemotherapy (CRS-HIPEC) on an Enhanced Recovery Pathway

M.D. Anderson Cancer Center

Phase 3 Completed
75 enrolled 21 charts

Peritoneal Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡